SynAct Pharma completes recruitment and dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients
SynAct Pharma AB ("SynAct") today announced that dosing in part 2 of the exploratory clinical Phase 2 study with AP1189 in Covid-19 patients conducted under the RESOVIR collaboration has been completed. The study is a randomized double-blind placebo-controlled study in 54 Covid-19 patients at clinical sites at Universidade Federal de Minas, Belo Horizonte, Brazil.The aim of the study is to evaluate the safety and efficacy of a two-week dosing regimen with AP1189 vs placebo as add-on therapy in patients with Covid-19 induced pulmonary insufficiency, defined as a need for supplementary oxygen